Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 12/20 | 0.79 |
| ▸ | ABL2 | P42684 | 3/20 | 0.79 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.79 |
| ▸ | RET | P07949 | 3/20 | 0.72 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.66 |
| ▸ | KDR | P35968 | 4/20 | 0.66 |
| ▸ | KIF5B | P33176 | 1/20 | 0.64 |
| ▸ | CCDC6 | Q16204 | 1/20 | 0.64 |
| ▸ | KIT | P10721 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24283328 | 1.00 | ABL1 (0.79) | ABL1ABL2MAPK14RETFGFR1 | |
| SCHEMBL21843620 | 0.95 | ABL1 (0.78) | ABL1ABL2MAPK14RETFGFR1 | |
| SCHEMBL31474781 | 0.95 | ABL1 (0.78) | ABL1ABL2MAPK14RETFGFR1 | |
| SCHEMBL21843524 | 0.89 | RET (0.70) | ABL1ABL2MAPK14RETFGFR1 | |
| SCHEMBL21843575 | 0.89 | ABL1 (0.76) | ABL1ABL2MAPK14RETFGFR1 | |
| SCHEMBL31474783 | 0.89 | ABL1 (0.76) | ABL1ABL2MAPK14RETFGFR1 | |
| SCHEMBL21843651 | 0.88 | RET (0.72) | ABL1ABL2MAPK14RETFGFR1 | |
| SCHEMBL31060358 | 0.88 | ABL1 (1.00) | ABL1ABL2MAPK14RETFGFR1 | |
| SCHEMBL15061726 | 0.87 | ABL1 (0.67) | ABL1ABL2MAPK14RETFGFR1 | |
| SCHEMBL21843537 | 0.87 | ABL1 (0.77) | ABL1ABL2MAPK14RETFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113227094-B | Alkynyl nicotinamide compounds as kinase inhibitors | 普渡研究基金会 | 2025-02-11 | — | — | CN | disclosed |